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325 Abstract 
26 Objective: Androgen excess in childhood is a common presentation and may signify sinister 
27 underlying pathology. Data describing its patterns and severity are scarce, limiting the information 
28 available for clinical decision processes. Here, we examined the differential diagnostic value of serum 
29 dehydroepiandrosterone sulfate (DHEAS), androstenedione (A4), and testosterone (T) in childhood 
30 androgen excess.
31 Design: Retrospective review of all children undergoing serum androgen measurement at a single 
32 center over 5 years. 
33 Methods: Serum A4 and T were measured by tandem mass spectrometry, DHEAS by immunoassay. 
34 Patients with at least one increased androgen underwent phenotyping by clinical notes review.
35 Results: In 487 children with simultaneous DHEAS, A4, and T measurements, we identified 199 with 
36 androgen excess (140 pre- and 59 post-pubertal). Premature adrenarche (PA) was the most common 
37 pre-pubertal diagnosis (61%), characterized by DHEAS excess in 85%, while A4 and T were only 
38 increased in 26% and 9%, respectively. PCOS was diagnosed in 40% of post-pubertal subjects, 
39 presenting equally frequent with isolated excess of DHEAS (29%) or T (25%) or increases in both A4 
40 and T (25%). CAH patients (6%) predominantly had A4 excess (86%); T and DHEAS were increased 
41 in 50% and 33%, respectively. Concentrations increased above the two-fold upper limit of normal 
42 were mostly observed in PA for serum DHEAS (>20fold in the single case of adrenocortical 
43 carcinoma), and in CAH for serum androstenedione.
44 Conclusions: Patterns and severity of childhood androgen excess provides pointers to the underlying 
45 diagnosis and can be used to guide further investigations. 
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447 Introduction
48 Androgen excess in childhood may present with a variety of symptoms and is thought to have 
49 a broad spectrum of underlying pathologies (1). Premature pubic and axillary hair growth, change in 
50 body odor and transient growth acceleration are typical presenting signs in pre-pubertal children (2); 
51 menstrual disturbances with hirsutism are presenting features in post-pubertal girls (3). In the vast 
52 majority of affected pre-pubertal children, premature adrenarche (PA) is the underlying diagnosis, 
53 whereas adolescent polycystic ovary syndrome (PCOS) is the leading cause of androgen excess in 
54 pubertal girls after menarche (1, 2, 4). Importantly, the diagnosis of PA and PCOS require exclusion 
55 of other causes of androgen excess such as inborn steroidogenic enzyme defects, most commonly 
56 congenital adrenal hyperplasia (CAH), precocious puberty or potentially malignant virilizing adrenal 
57 tumors, with the latter being extremely rare in childhood (1, 5, 6). 
58 To reach a conclusive diagnosis in a child presenting with androgen excess can be 
59 challenging. Detailed history, including onset, acuity, severity and progression of symptoms and a 
60 thorough clinical examination, followed by hormonal investigations, bone age assessment, and, where 
61 appropriate, imaging studies, are part of the clinical work-up (1, 7). The extent of investigations 
62 required usually depends on the severity and acuity of presenting symptoms, and clinicians tend to 
63 tailor those investigations depending on the clinical presentation and the severity of biochemical 
64 androgen excess (7). However, there is a paucity of data from larger cohorts delineating patterns and 
65 severity of childhood androgen excess considered predictive for both common and rare underlying 
66 pathologies. 
67 Physiologically low circulating androgen levels in children and the widespread use of 
68 radioimmunoassays, which are prone to cross-reactivity and low sensitivity, limit the diagnostic 
69 accuracy of the measurement of the serum concentrations of the active androgen testosterone (T) and 
70 the androgen precursors androstenedione (A4) and dehydroepiandrosterone sulfate (DHEAS), in 
71 particular when measured in isolation (8, 9). Liquid chromatography-tandem mass spectrometry (LC-
72 MS/MS) analysis of serum steroids has emerged as a highly sensitive analytical tool, in particular 
73 when measuring low-abundance steroids in children (10, 11). To date, there is a dearth of data on LC-
74 MS/MS based androgen measurements in childhood androgen excess conditions. 
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575 We have recently reported the utility of simultaneous measurement of serum DHEAS, A4 and 
76 T in determining causes, patterns and severity of androgen excess in a large sample of adult women 
77 recruited in a single center (12), generating useful guidance for clinicians to predict non-PCOS 
78 pathology in adult women presenting with androgen excess. In this study, we aimed to develop the 
79 evidence base for a rational approach to childhood androgen excess. To this end, we analyzed a large 
80 cohort of consecutively recruited children from a single tertiary referral center to uncover the 
81 signatures of distinct conditions underlying childhood androgen excess. 
82 PATIENTS AND METHODS
83 Subjects and Clinical Protocol
84 Institutional review board approval for retrospective data review was obtained from 
85 Birmingham Womens and Childrens Hospital (BWCH) NHS Foundation Trust (reference: CARMS-
86 00935).  We included all children who had undergone measurements of serum T, A4 and DHEAS as 
87 part of routine clinical care at BWCH between 1st January 2013 and 1st June 2017 (n=1,525), 
88 identifying 487 who underwent simultaneous measurement of DHEAS, A4 and T. Samples were 
89 collected at variable times during the day in the context of out-patient clinic appointments. Patients 
90 with at least one serum androgen concentration increased above the Tanner stage-specific reference 
91 range (n=199) underwent further clinical phenotyping by case note review, extracting information on 
92 clinical presentation, medical history, height, weight, BMI, bone age, ethnicity, and the underlying 
93 cause of androgen excess, as supported by clinical, biochemical and radiological findings in each case 
94 with final review by a board-certified pediatric endocrinologist (V.S., T.G.B., N.J.S., N.K., R.P.D., 
95 M.K., J.K., W.H., R.E.K.). Reference data for standardized BMI (BMI SDS) were obtained from the 
96 British 1990 dataset (13). 
97 Serum androgen measurements
98 Biochemical androgen excess was defined as a serum concentration increased above a local, 
99 age-specific reference range (for DHEAS) or above the Tanner-stage specific normative reference 
100 range  as reported in (14) for A4 and T. Serum A4 and T were analyzed by liquid chromatography-
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6101 tandem mass spectrometry on a Shimadzu Prominence XR UPLC coupled to a Sciex 6500 Triple 
102 Quad mass spectrometer as described previously (12). Briefly, samples are analyzed by liquid-liquid 
103 extraction following addition of deuterated internal standards and separated chromatographically 
104 using an isocratic elution profile, ionized using positive atmospheric pressure chemical ionization 
105 (APCI) and detected according to compound-specific transitions. Serum DHEAS was analyzed using 
106 the Roche competitive electrochemiluminescence immunoassay on the Roche Cobas c702 analyzer 
107 (12).
108 Statistical analysis
109 GraphPad Prism® was used for statistical analysis and generation of graphs. Data were 
110 expressed as median and first and third quartile, unless otherwise stated. The Mann-Whitney U test 
111 was used for comparison between two groups (pre- and post-pubertal). Spearman Rank correlation 
112 was employed to assess correlation between two non-evenly distributed variables. Statistical 
113 significance was set at p<0.05.
114 RESULTS
115 Description of the cohort and diagnostic spectrum
116 A total of 1,525 children had at least one serum concentration of DHEAS, A4 or T measured 
117 during the study period. In 487 children (31.9%), all three androgens had been measured 
118 simultaneously and were taken forward as the analysis cohort (Fig. 1). When applying age-defined 
119 cut-offs, 255 children (52.4%) had at least one increased serum androgen; however, when applying 
120 Tanner stage-defined cut offs, thus taking into account pubertal development, only 199 children 
121 (40.9%) had androgen excess (Fig. 1). Those 199 children were phenotypically further characterized 
122 as described in the Methods section. There was a pre-dominance of girls (Table 1). The median BMI 
123 SDS was increased in the overall cohort and higher in the pubertal than in the pre-pubertal group 
124 (Table 1). The overall cohort was ethnically diverse, with the two largest group comprising Caucasian 
125 children (44.2%) and children of South Asian ethnicity (38.7%) (Table 1).
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7126 The overall majority of pre-pubertal children had a diagnosis of PA (n=86; 61%), while at 
127 pubertal age PCOS was the most common diagnosis (n=24; 40%) (Fig. 1). In both subgroups, rare 
128 and very rare underlying causes of androgen excess were also identified, including congenital adrenal 
129 hyperplasia (CAH; 7.0%), isolated premature menarche (IPM; 2.5%), central precocious puberty 
130 (cPP; 2.5%) and one case each of adrenocortical carcinoma (ACC) and Cushings disease (CD). In 
131 about one third of cases, miscellaneous diagnoses and features were reported or no associated 
132 diagnosis was made (Fig. 1; Suppl. Table 1).  
133 The majority of the 86 children with PA were girls (79%). Girls with PA presented at a 
134 median age of 7.2 years, boys at 8.2 years. 41 PA children (48%) were of Caucasian ethnicity, 31 
135 children (26%) of South-Asian and 12 children (14%) of Afro-Caribbean descent; the general 
136 population in the local area has been recorded as 58.0% Caucasian, 22.5% South Asian, and 9% Afro-
137 Carribean (15). There were no notable gender differences with regards to clinical presentation (Suppl. 
138 Table 2), although acne was rare in boys. The median bone age advancement in the PA cohort was 
139 1.88 years (IQR 1.16, 2.33). None of the subjects had notable co-morbidities or were on any regular 
140 medication. 
141 In subjects diagnosed with adolescent PCOS, the median age at presentation was 15.2 years 
142 (IQR 13.1, 15.7). The majority was of South-Asian ethnicity (n=18; 75%); three were Caucasian 
143 (12.5%) and two girls were African-Caribbean (8%). The diagnosis of PCOS was established on the 
144 basis of the presence of an irregular menstrual cycle and biochemical features of androgen excess. In 
145 addition, 63% (n=15) girls also had clinical signs of androgen excess (hirsutism and/or acne) and 
146 seven subjects complained about weight gain (29%). The median BMI of the PCOS subjects was 27.1 
147 kg/m2 (2.24 SDS; IQR 0.91, 2.58). None of the PCOS subjects had significant co-morbidities, and 
148 they were not on any anti-androgenic medication or metformin at presentation. 
149 All 14 CAH patients had a genetically confirmed diagnosis of 21-hydroxylase (CYP21A2) 
150 deficiency; 12 had the classic salt-wasting form and two subjects had non-classic CAH. All classic 
151 CAH cases were on steroid replacement therapy; the non-classic cases were not on medication. 
152 We identified five girls with isolated premature menarche (IPM) and five with central 
153 precocious puberty (cPP). All IPM cases presented with isolated vaginal bleeding. All girls with cPP 
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8154 presented with early breast development and additional signs of androgen excess (premature pubarche 
155 n=4; early development of axillary hair n=3; acne n=2).  As extremely rare cases, one boy presented 
156 with adrenocortical carcinoma (ACC) and one boy with Cushings disease (CD). The ACC case 
157 presented at the age of 1.8 years with peripheral precocious puberty. The boy with CD presented at 13 
158 years of age with weight gain, easy bruising, headaches and typical Cushingoid appearance and was 
159 found to have an ACTH-producing pituitary micro-adenoma.
160  Patterns of androgen excess according to the underlying diagnosis
161 Isolated DHEAS excess was the most common biochemical presentation in children 
162 presenting with PA (n=58; 67.4%) (Fig. 2A). 11 PA subjects (12.8%) had a combination of DHEAS 
163 and A4 excess. Isolated A4 or T excess was rare in PA and only found in nine (10.5%) and four 
164 (4.7%) subjects. A pattern with all three androgens elevated was only observed in three PA subjects 
165 (3.5%).  In adolescent PCOS, patients equally frequently presented withisolated DHEAS excess 
166 (29%), isolated T excess (25%) or increased serum concentrations of both A4 and T (25%) (Fig. 2B). 
167 Children with CAH predominantly presented with A4 excess (86%); T and DHEAS were 
168 incrased in 50% and 33%, respectively.(Fig. 2C). Isolated DHEAS was never observed in CAH 
169 children, and only one pre-pubertal CAH patient presented with isolated T excess and increases in all 
170 three androgens, respectively. In the ACC case, both DHEAS and A4 were increased, the CD case 
171 had isolated A4 excess. 
172 Severity of Androgen Excess 
173 In children with PA, serum DHEAS was mostly increased one to two-fold above the upper 
174 limit of normal (ULN) and did not exceed 8-fold ULN (Fig. 3A; Suppl. Table 3). PA girls had higher 
175 DHEAS than boys (p=0.036) (Suppl. Table 3; Suppl. Fig. 1). The single ACC case presented with 
176 serum DHEAS increased to 28-fold ULN. The majority of children with CAH had normal DHEAS 
177 levels (Fig. 3A; Suppl. Table 3). 
178 A4 excess above two-fold ULN was typically observed in classic CAH patients (Fig. 3B; 
179 Suppl. Table 3). Mild to moderate A4 excess (one- to two-fold ULN) was observed in adolescent 
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9180 PCOS (42%), in some children with PA (24%) and in the ACC case. The boy with CD had severe A4 
181 excess. In PA, A4 was higher in boys than girls (p = 0.0008) (Suppl. Fig. 1).
182 Both mild to moderate (one- to two-fold ULN) and severe (>two-fold ULN) excess of serum 
183 T was found in a number of subjects with PA, PCOS and CAH (Fig. 3C; Suppl. Table 3). T excess 
184 was found in a minority of children with PA (10%), but 2 boys had severe T excess; overall, serum T 
185 did not differ between boys and girls with PA (Suppl. Fig. 1). In PCOS, T excess was found in 63% 
186 of cases, but was severe in one only (Fig. 3 C). In classic CAH, six subjects (50%) had T excess, 
187 which was severe (5-fold elevation) in one adolescent girl.
188 DISCUSSION
189 Here we have simultaneously measured the serum concentrations of the androgen precursors 
190 DHEAS and A4 as well as the active androgen T in 487 consecutively recruited children and 
191 adolescents in a single tertiary paediatric referral center, covering a population of 5.5 million. The size 
192 of our cohort, comprising 199 children with biochemically confirmed androgen excess, enabled us to 
193 provide separate analyses of androgen excess pattern and severity in the pre- and post-pubertal age 
194 subgroups. Our study cohort included children presenting with clinical features of androgen excess, 
195 but also patients with suspicion of complex adrenal and gonadal pathologies, increasing the diverse 
196 and complex spectrum of underlying conditions. This enriched our study population for rare and very 
197 rare diagnoses. The study population was ethnically very diverse; in comparison to the local 
198 background population, there was some over-representation of South Asian and African-Carribean 
199 ethnicities in PA children and particular over-representation of South-Asian ethnicity in the PCOS 
200 group. This may partially reflect the higher incidence of PCOS in South Asian subjects (16) as well as 
201 the proximity of our center to areas with higher ethnic diversity within the overall catchment area. 
202 Previous studies have assessed serum androgens in pre-selected samples of children with 
203 distinct androgen excess conditions, mainly PA and adolescent PCOS. PA has been studied over the 
204 past 30 years in several case-control studies, in well described cohorts consisting of 10-100 study 
205 subjects of various ethnical-geographical backgrounds, but mainly focusing on metabolic 
206 consequences in PA (see (1, 2, 17, 18) for comprehensive reviews), however, generally without 
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207 providing full details on androgen metabolism including severity levels. Two studies reported 
208 immunoassay-based androgen concentrations in subjects with PA (19, 20): Virdis et al (1993) 
209 reported elevated DHEAS levels in the majority of subjects up to 9-fold above the upper limit of age-
210 matched controls, but normal A4 and T excess only in most subjects studied (19). Voutilainen (1983) 
211 did not report DHEAS levels, but found that unconjugated DHEA and A4 were up to 5-fold elevated 
212 in 18 PA subjects studied (20).
213 Adrenal androgen excess with elevated serum DHEAS above the age specific-reference range 
214 and a marginal increase in downstream androgens is recognized as a key feature of PA (2, 21); others 
215 suggested increased serum DHEAS appropriate for Tanner pubertal stage but increased when 
216 referring to age-specific reference ranges (22, 23). Of note, the pattern and severity of androgen 
217 excess in PA has not been analyzed in detail previously, neither how these differentiate PA from other 
218 conditions presenting with androgen excess such as CAH or other even rarer causes. 
219 In our cohort, increased serum DHEAS was detected in the majority of children with PA 
220 while A4 and T were increased only in a minority of subjects, despite clinical evidence of increased 
221 androgen action. DHEAS is an inactive metabolite with no affinity to the androgen receptor, 
222 suggesting that downstream conversion of de-sulfated DHEA to potent androgens could occur within 
223 the target tissues of androgen action. Our group and others have recently highlighted 11-oxygenated 
224 androgens as a major source of androgen excess in conditions like PCOS and CAH (24, 25, 26, 27). 
225 The adrenal P450 cytochrome 11ß-hydroxylase (CYP11B1) enzyme efficiently converts A4 to 11-
226 hydroxy-androstenedione, which can be further converted to 11-ketotestosterone (11KT), which has 
227 been shown to bind and activate the androgen receptor with similar potency to T (24, 28, 29). In fact, 
228 11KT has very recently been shown to feature prominently in children with PA (30), supporting the 
229 theory that androgenic effects in PA may be mediated via increased 11-oxygenated androgens. 
230 However, measurement of 11-oxygenated androgens does not yet form part of routine androgen 
231 assessment in childhood androgen excess and, thus, was not measured in our cohort.
232 Radioimmunoassays (RIAs) were employed in the past in studies assessing androgen 
233 metabolism in children, in particular the initial reports from the 1970s (31, 32), which are frequently 
234 referenced. RIAs are prone to cross-reactivity and less sensitive to lower circulating concentrations 
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235 usually found in children. Our study has employed more sensitive and specific tandem mass 
236 spectrometry (LC-MS/MS) for the measurement of A4 and T. Clinical biochemistry laboratories are 
237 now using mass spectrometry-based steroid panels with increasing frequency, which confronts the 
238 clinician often with more results than requested in the first place. Our findings can provide guidance 
239 for risk stratification in the assessment of childhood androgen excess.  
240 Only recently, LC-MS/MS-based longitudinal measurements of androgens were reported in 
241 40 obese girls with adolescent PCOS (33). Interestingly, that study reported elevated A4 and T levels, 
242 but normal DHEAS compared to BMI-matched controls. This is in contrast to this study, but also our 
243 previous report on pre-menopausal PCOS women (12), where elevated serum DHEAS was the most 
244 common finding. We used standard reference values obtained from a lean cohort (14), which is 
245 probably most appropriate for daily clinical practice when referring to reference data. 
246 In order to biochemically characterize common childhood androgen excess conditions, the 
247 patterns and severity of androgen levels may help the clinician to discriminate non-PA and non-PCOS 
248 pathology. Children with CAH presented pre-dominantly with A4 and T excess. Certainly, 17OHP 
249 elevation would be the key biochemical discriminator to detect of the most common form of CAH, 
250 21-hydroxylase deficiency, and should be included in the diagnostic work-up of childhood androgen 
251 excess (1, 7). A basal serum 17OHP threshold of  2 ng/ml (6 nmol/L) has been shown to distinguish 
252 PA from non-classic CAH with high sensitivity and specificity (34). All the patients with classic CAH 
253 in our cohort were on hydrocortisone replacement therapy and hence severity and pattern of androgen 
254 excess will be distinct from androgen excess in newly diagnosed CAH patients. However, the serum 
255 androgen signatures observed in our CAH study sample form a very characteristic profile, which is 
256 helpful for the clinician in interpreting serum androgen profiles to differentiate CAH from other 
257 disorders associated with adnrogen excess. 
258 Previous work has provided limited information on circulating androgens in girls with central 
259 precocious puberty (cPP) or isolated premature menarche (IPM). Pubic or axillary hair development 
260 are rarely part of the spectrum in IPM (35), but have been reported in more than 60% of children with 
261 cPP (36). All girls with cPP (but none of the girls with IPM) in our cohort had additional (early) 
262 pubarche, which prompted the assessment of serum androgens. In our study, all five girls with IPM 
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263 had mild DHEAS excess, which could reflect concomitant (or pre-existing) exaggerated adrenarche. 
264 Indeed it has been shown that higher adrenal androgens are linked to an earlier onset of puberty with a 
265 shorter peak height velocity (37). The underlying etiology of IPM is not well understood, and it is 
266 considered to be a benign, self-limiting condition (35). However, one might speculate that 
267 aromatization of excess androgens could expose the endometrium to higher levels of estrogens, 
268 enhancing the build-up of the endometrial lining, ultimately resulting in menarche. 
269 Adrenocortical carcinoma (ACC) is an extremely rare entity in children, apart from certain 
270 geographical areas like Brazil where ACC is more prevalent due to a distinct founder mutation 
271 (p.R337H) of the TP53 gene (38). The general rarity of ACC is also reflected in our study population 
272 with a single case diagnosed in 487 children over a 5-year study period. Interestingly, our patient also 
273 carried the Brazilian TP53 founder mutation, although the family was of South Asian origin. Based on 
274 a recent larger case series of children with ACC from the US (41 cases identified over a period of 60 
275 years), androgen excess is the most frequently presenting steroid abnormality in childhood ACC (39). 
276 Details on serum androgen concentrations at presentation, however, are not widely reported in 
277 childhood ACC, presumably due to the rarity of the disease, complicated by historic nature of cases 
278 and varying assay methodologies. Based on our study and what is known from the literature, the 
279 findings certainly indicate that severe DHEAS excess beyond 8-fold ULN should prompt urgent 
280 further investigations to exclude ACC-related androgen excess. 
281 In conclusion, we have undertaken a detailed analysis of pattern and severity of androgen 
282 excess in a large cohort of children of pre- and post-pubertal age. Our findings provide unique insights 
283 into the variety and frequency of childhood androgen excess conditions and the utility of combined 
284 measurements of serum DHEAS, A4 and T. DHEAS excess is rare in CAH, which typically features 
285 A4 excess. In contrast, DHEAS excess is characteristic for PA and frequently found in adolescent 
286 PCOS; serum DHEAS increased above 8-fold ULN should prompt the clinician to perform further 
287 investigations to exclude sinister underlying pathology. 
288
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411 FIGURE LEGENDS
412
413 Fig. 1: Flowchart of the distribution of diagnoses according to pre-pubertal vs. post-pubertal status in 
414 487 children who underwent simultaneous measurement of serum DHEAS, A4 and T. 
415 PA, premature adrenarche; CAH, congenital adrenal hyperplasia; IPM, isolated premature menarche; 
416 ACC, adrenocortical carcinoma; CD, Cushings disease; PCOS, polycystic ovary syndrome; cPP, 
417 central precocious puberty.
418
419 Fig. 2: Distribution of serum androgen excess patterns in (A) children with premature adrenarche, (B) 
420 girls with polycystic ovary syndrome and (C) children with congenital adrenal hyperplasia. White 
421 bars represent pre-pubertal subjects, black bars post-pubertal subjects. 
422
423 Fig. 3: Severity of androgen excess according to diagnosis and serum androgen measured. Median 
424 values for each diagnosis are denoted by a solid black or white line. Androgen excess levels are 
425 represented as fold increase above upper limit of normal (ULN); levels above 1 therefore indicate 
426 androgen excess, indicated by the black interrupted line. An arbitrary defined cut-off for severe 
427 androgen excess from 2-fold ULN is indicated by a black dotted line. 
428 PA, premature adrenarche; PCOS, polycystic ovary syndrome; DoP, disorders of puberty (closed 
429 circles: central precocious puberty; open circles: isolated premature menarche); CAH, congenital 
430 adrenal hyperplasia (closed circles: classic CAH; open circles: non-classic CAH); ACC, 
431 adrenocortical carcinoma; CD, Cushings disease.
432
Page 17 of 26 Accepted Manuscript published as EJE-18-0854.R1. Accepted for publication: 19-Dec-2018
Copyright © 2018 European Society of Endocrinology
Downloaded from Bioscientifica.com at 01/04/2019 10:47:10AM
via University Sheffield
Table 1: Baseline demographics of 199 children with biochemical androgen excess as defined by 
serum concentrations above the reference range for at least one of three measured androgens 
(DHEAS, androstenedione, and testosterone).
* Ethnicity distribution pattern in the Birmingham area is: Caucasian 5  Asian 2 (South 
Asians 
225
other Asians 4
 


Afro-Caribbean 9

Mixed 4

4

and other 
2
 Source: 
United Kingdom Census 2011, Office for National Statistics (15).
 Total Pre-pubertal Pubertal
Patients with  of 3 androgens 
increased 
199 140 
(70.3%)
59 
(29.7%)
Age (years) 
Median (Q1, Q3) 
8.3
(6.8; 13.3)
7.4 
(4.6, 8.5)
14.9
(13.4, 15.6)
Gender
Girls 141 (70.8%) 89 (63.6%) 52 (88.1%)
Boys 58 (29.2%) 51 (36.4%) 7 (11.9%)
BMI (kg/m2) 
Median (Q1, Q3) 
19.5
(16.4; 25.1)
17.9
(15.9; 22.0)
26.8
(19.8; 31.0)
BMI SDS
Median (Q1, Q3)
1.35
(0.2; 2.6)
1.26
(-0.1; 2.5)
1.88
(0.6; 2.7)
Ethnicity*
Caucasian 91 (44.2%) 64 (44.2%) 27 (44.2%)
South Asian 76 (38.7%) 50 (36.9%) 26 (44.1%)
Afro-Caribbean 16 (8.0%) 13 (9.4%) 3 (4.9%)
Mixed background 3 (1.5%) 2 (1.5%) 1 (1.6%)
Other 1 (0.5%) 0 1 (1.6%)
Unknown 13 (6.5%) 11 (7.2%) 3 (4.9%)
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All children with serum 
DHEAS, A4 and T measured 
n=487
Pubertal children 
n=220 (45.2%)
≥1 increased 
androgen        
n=140 (52.4%)
Normal 
androgens
n=161 (73.2%)
PA
n=86 
(61.4%)
Other causes:
CAH n=6 (4.3%)
IPM n=5 (3.6%)
ACC n=1 (<1%)
CD n=1 (<1%)
Miscellaneous n= 41 
(29.3 %)
PCOS
n=24 
(40.1%)
Other causes:
CAH n= 8 (13.6%)
cPP n=5 (8.4%)
Miscellaneous n= 22 
(37.3%)
Normal 
androgens
n=127 (47.6%)
≥1 increased 
androgen        
n= 59 (26.8%)
Pre-pubertal children 
n=267 (54.8%)
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A PA - girls B PA - boys 
C CAH - girls D CAH - boys 
E PCOS F Disorders of Puberty
NCCAH
Central Precocious Puberty
Isolated Premature Menarche
(n=67) (n=19)
(n=8) (n=6)
(n=24) (n=10)
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A PA - girls B PA - boys 
C CAH - girls D CAH - boys 
E PCOS F Disorders of Puberty
NCCAH
Central Precocious Puberty
Isolated Premature Menarche
(n=67) (n=19)
(n=8) (n=6)
(n=24) (n=10)
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Suppl. 1: Miscellaneous diagnoses and features (as specified in Fig. 1) identified in 63 
patients with at least one serum androgen concentration increased above the Tanner stage-
specific reference range, but no conclusive diagnosis explaining androgen excess.
P	
	
N
P
	
N
Girl B Girl B
N=4 N=3 N=6 N=0D	ff fi		
l	y t 	
a	fl ffi 
fl	  flr	
	ea	
N=13
Clitoromegaly, 
resolving (n=2)
Bilateral adrenal 
hemorrhages 
Clitoromegaly 
(resolved)
Hypertrichosis, 
resolving 
Germ cell tumor Isolated acne (n=2)
Isolated thelarche A !"#$%&&'("an-
Hormone 
resistance 
Oligomenorrhea 
(resolved)
Excessive sweating
Mood swings
N=13 N=21 N=13 N=3D	ff fi		
 l	  	
a	fl ffi 
fl	  flr	
	ea	
N=50
No diagnosis (n=5) No diagnosis 
(n=9)
Simple Obesity 
(n=9)
Delay of growth 
and puberty
Complex cloacal 
anomaly 
Micropenis (n=2) Road traffic 
accident
Buried penis, 
impalpable testes
Electrolyte 
abnormalities
Klinefelter 
syndrome
Bardet Biedl 
Syndrome
Wiedemann 
Beckwith 
Syndrome
Primary ovarian 
failure
Septo-optic 
dysplasia (n=2)
Atopic skin
Alström syndrome 
(n=2)
Pubertal arrest/ 
primary gonadal 
failure
Silver Russell 
Syndrome
CHARGE 
syndrome
CHARGE 
syndrome
Obesity Hypospadias 
(n=2)
Aldosterone 
synthase deficiency
Alström syndrome
Prader Willi 
syndrome
Supra-sellar cyst
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Suppl. Tabl  Clinical signs and symptoms in children presenting with premature 
adrenarche
Total Girls Boys
Premature Pubarche
Premature development ir 25 21 4
Tall stature/ growth acceleration 21 4
Acne 14 13 1
14 11 3
lopment/ gynecomastia 12 11 1
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1Suppl. Tabl) 3: Severity of androgen +,-+ss in children 1./ according to underlying diagnosis. Serum androgen data are presented as fold increased above the 
upper lim06 78 :7;m<= >?@CE <:F <s absolute serum conce:6;<607:nG H76I +,J;+nn+F <n m+dian value a:F 0:6+; KL<;60=+ ;<:M+n >OQREG 08 <JJ;7J;0<6e. 
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